scholarly journals Caseating Granulomatous Inflammation: Think beyond Tuberculosis

2013 ◽  
Vol 3 (2) ◽  
pp. 51-54
Author(s):  
Padmavathi Devi Chaganti ◽  
YVS Prabhakar ◽  
KA Seetaram ◽  
Kalyan Babu
Keyword(s):  
Human Immunodeficiency Virus ◽  
Gastrointestinal Tract ◽  
Antiretroviral Therapy ◽  
Lymph Nodes ◽  
Granulomatous Inflammation ◽  
Positive Patient ◽  
Hiv Positive ◽  
Antituberculous Treatment ◽  
Immunodeficiency Virus

ABSTRACT A 33 years old male human immunodeficiency virus (HIV) positive patient on antiretroviral therapy developed caseating granulomatous inflammation of lymph nodes. He did not respond to antituberculous treatment. Subsequently, he developed gastrointestinal tract lesions. Special stains show positivity for histoplasmosis The case is presented because of its resemblance to tuberculosis. How to cite this article Chaganti PD, Prabhakar YVS, Seetaram KA, Babu K. Caseating Granulomatous Inflammation: Think beyond Tuberculosis. Int J Phonosurg Laryngol 2013;3(2):51-54.

Pneumocystis carinii infection in bilateral aural polyps in a human immunodeficiency virus-positive patient

2002 ◽  
Vol 116 (4) ◽  
pp. 288-290 ◽  
Author(s):  
C. V. Praveen ◽  
R. M. Terry ◽  
M. Elmahallawy ◽  
C. Horsfield
Keyword(s):  
Human Immunodeficiency Virus ◽  
Opportunistic Infection ◽  
Pneumocystis Carinii ◽  
Lymphatic Vessels ◽  
Blood Stream ◽  
Positive Patient ◽  
Hiv Positive ◽  
Immunodeficiency Virus ◽  
History Of ◽  
Pneumocystis Carinii Infection

Pneumocystis carinii is an opportunistic infection found in patients with impaired immunity. Under favourable conditions the parasite can spread via the blood stream or lymphatic vessels and cause extrapulmonary dissemination. We report a case of P carinii infection presenting as bilateral aural polyps, otitis media and mastoiditis in human immunodeficiency (HIV)-positive patient with no history of prior or concomitant P carinii infection.

Conjunctival Non-Caseating Granulomas in a Human Immunodeficiency Virus (HIV) Positive Patient Attributed to Sarcoidosis

2006 ◽  
Vol 14 (5) ◽  
pp. 309-311 ◽  
Author(s):  
Thekla G. Papadaki ◽  
Chrysanthi Kafkala ◽  
Ioannis P. Zacharopoulos ◽  
Jian Seyedahmadi B ◽  
Thaddeus Dryja ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Positive Patient ◽  
Hiv Positive ◽  
Immunodeficiency Virus

Exuberant mucocutaneous lesions of disseminated histoplasmosis in a human immunodeficiency virus (HIV) positive patient

2009 ◽  
Vol 48 (2) ◽  
pp. 157-159 ◽  
Author(s):  
Marcello Menta S. Nico ◽  
Hermes Ryoiti Higashino ◽  
Ho Yeh Li ◽  
Noemia Barbosa Carvalho ◽  
Silvia Vanessa Lourenço
Keyword(s):  
Human Immunodeficiency Virus ◽  
Positive Patient ◽  
Hiv Positive ◽  
Disseminated Histoplasmosis ◽  
Immunodeficiency Virus

scholarly journals Evaluation of Kidney Function Tests in HIV-Positive Patients Receiving Combined Antiretroviral Therapy

2021 ◽  
Author(s):  
emre aydın ◽  
Fatma Yılmaz Aydın ◽  
Yakup Demir ◽  
Yaşar Yıldırım ◽  
Mustafa Kemal Çelen
Keyword(s):  
Human Immunodeficiency Virus ◽  
Glomerular Filtration Rate ◽  
Antiretroviral Therapy ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Hiv Positive ◽  
Group 4 ◽  
Immunodeficiency Virus ◽  
Combined Antiretroviral Therapy ◽  
Group 5

Introduction: Human Immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some retroviral therapies have a higher nephrotoxicity potential. As a result of renal injury, serum creatinine increases, and the estimated glomerular filtration rate is reduced. The aim of our study was to assess changes in kidney function during a 24-month period in HIV-positive patients who were begun on combined antiretroviral therapy. Material-method: A total of 127 HIV positive patients were enrolled. The patients were divided into five groups; patients who received no therapy were designated as Group 1; those that received Dolutegravir/Abacavir/Lamivudine combination as Group 2; those that received Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate combination as Group 3; those that received Emtricitabine/Tenofovir Disoproxil Fumarate/Dolutegravir combination as Group 4; and those that received Emtricitabine/Tenofovir Disoproxil Fumarate/Raltegravir combination as Group 5. We compared the effects of these drugs on estimated glomerular filtration rate during a 24-month follow-up period. Results: At the 24th month of therapy, a significant difference was observed between the eGFR levels of the study groups (p:<0.001). eGFR level was significantly higher in Group 4 compared to Groups 1, 2, and 3 (p:0.009, p:<0.001, p:<0.001, respectively) while it was significantly lower in Group 5 than groups 1, 2, and 3 (p:0.005, p:<0.001, p:<0.001, respectively). No significant eGFR difference was found between Group 4 and Group 5 (p>0.05). Serum creatinine level was significantly higher in Groups 4 and 5 compared to the other groups (p<0.001). Conclusion: The use of TDF-containing regimens causes renal dysfunction. Therefore, we recommend close monitoring of renal function, especially in patients treated with TDF.

AchR myasthenia gravis (MG) atypical presentation in human immunodeficiency virus (HIV) positive patient

2021 ◽  
Vol 429 ◽  
pp. 118363
Author(s):  
Alessandro Di Santo ◽  
Fabio Pilato ◽  
Fioravante Capone ◽  
Liana Africa ◽  
Vincenzo Di Lazzaro
Keyword(s):  
Human Immunodeficiency Virus ◽  
Myasthenia Gravis ◽  
Positive Patient ◽  
Hiv Positive ◽  
Atypical Presentation ◽  
Immunodeficiency Virus

Reduction in Size and Number of Plantar Verrucae in Human Immunodeficiency Virus–Infected Individuals After the Implementation of Highly Active Antiretroviral Therapy

2015 ◽  
Vol 105 (5) ◽  
pp. 401-406 ◽  
Author(s):  
Endri Afesllari ◽  
Timothy J. Miller ◽  
Michael J. Huchital ◽  
Christy M. King ◽  
James S. Johnston ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Clinical Manifestations ◽  
Hiv Positive ◽  
Highly Active ◽  
Clinical Type ◽  
Size Number ◽  
Study Results ◽  
Immunodeficiency Virus

Background Implementation of highly active antiretroviral therapy (HAART) significantly increased the life expectancy of those living with human immunodeficiency virus (HIV). Except for prevalence, scientific reports regarding clinical manifestations of plantar verrucae in the post-HAART era are lacking. The objective of this study was to compare clinical manifestations of plantar verrucae between HIV-infected and noninfected individuals and then to compare these findings with those observed before the implementation of HAART. Methods Nineteen patients with plantar verrucae (ten with HIV and nine without HIV) were examined to determine the size, number, and clinical type of verrucae present. The two groups were first compared with each other and then with previously collected data from a similar analysis conducted in 1995, before the implementation of HAART. Statistical significance was determined using the Fisher exact test or the Wilcoxon rank sum test. Results No significant differences were observed in the size, number, or clinical type of verrucae between HIV-negative and HIV-positive patients. Compared with the 1995 data, there was a significant decrease in the number of verrucae lesions per individual and a nonsignificant decrease in the average size of verrucae in HIV-positive patients. Conclusions Study results indicate that the implementation of HAART has impacted the clinical manifestations of plantar verrucae in HIV-positive individuals. Further analyses with a larger number of patients are required to confirm and substantiate these findings.

Sign in / Sign up

Export Citation Format

Share Document